Develop blood-based diagnostic tests. Focus on early detection of pancreatic cancer. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 5% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 43.3× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $71K a year. A small number, but proof the product has real buyers.
A loss of $15.0M against $71K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.01. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.